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Edited by Gianni CesareniAbstract To investigate additional functions of the T cell
adaptor, Src homology 2 (SH2) domain-containing leukocyte
protein of 76 kD (SLP-76), we performed a yeast two-hybrid
assay using the N-terminal region of SLP-76 fused with the
kinase domain of Syk. By screening a human leukemia cDNA
library, we identiﬁed the p85 subunit of phosphoinositide 3-
kinase (PI3K) as one of the interacting molecules. Unlike the
SH2 domain of Vav or Nck, tyrosine phosphorylation of SLP-76
at position 113 or 128 was suﬃcient for it to associate with the
N-terminal SH2 of p85. Collectively, these data suggest that
SLP-76 may play a role in PI3K signaling pathways.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Src homology 2 (SH2) domain-containing leukocyte phos-
phoprotein (SLP-76) is a hematopoietic cell-speciﬁc adaptor
protein that is phosphorylated by ZAP-70, a member of the
Syk family of protein tyrosine kinases (PTK) after ligation of
the T cell receptor (TCR) [1,2]. SLP-76 contains motifs that
allow for protein–protein interactions and plays an important
role in regulating signaling from the TCR [3–5].
An amino-terminal acidic region of SLP-76 (N-SLP) con-
tains tyrosine phosphorylation sites at positions 113, 128, and
145 [4,6–9], and phosphorylation at positions 113 and 128 is
known to be critical for transducing the TCR signal and ac-
tivating the T cells [4]. A proline-rich motif in the central re-* Corresponding author. Fax: +82-2-3277-3760.
E-mail address: jrlee@ewha.ac.kr (J.R. Lee).
Abbreviations: SH2, Src homology 2; SLP-76, Src homology 2 domain-
containing leukocyte phosphoprotein of 76 kD; PI3K, phosphoinosi-
tide 3-kinase; PTK, protein tyrosine kinase; TCR, T cell receptor; Ab,
antibody; IP, immunoprecipitation; IB, immunoblotting; WT, wild-
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members [3,10–12], and a carboxyl-terminal SH2 domain (C-
SLP) forms signaling complexes by interacting with proteins
newly phosphorylated on tyrosine residues [3,13–15]. The
schematic diagram of full length SLP-76 is shown in Fig. 1A.
The importance of SLP-76 in T cell signaling has been
demonstrated in experiments with the Jurkat human T cell
leukemia line and in mice made deﬁcient for SLP-76 expression
by homologous recombination [16–18]. When SLP-76 is
overexpressed in Jurkat cells, there is a dramatic augmentation
of TCR-mediated activation of the full-length IL-2 promoter
or of a reporter construct driven by nuclear factor of activated
T cells (NFAT) from the IL-2 promoter [3–5]. Overexpression
of SLP-76 mutants lacking each of the three structural do-
mains has been shown to be unable to promote TCR-mediated
activation events, suggesting that molecular associations in-
volving each of the three domains of SLP-76 are required for
optimal function [5]. It is crucial therefore to identify the
proteins with which SLP-76 interacts in order to understand
how it promotes TCR signaling.
To identify molecules that associate with tyrosine-
phosphorylated SLP-76, we performed a yeast two-hybrid assay
by screening a human T cell leukemia cDNA library with a fu-
sionof SLP-76with the kinase domainof SykPTK (N-SLP-Syk)
as bait. We identiﬁed the p85 subunit of phosphoinositide 3-
kinase (PI3K) as one of the molecules that associates with N-
SLP in a Syk-dependent manner. Experiments with mutants
lacking various functional domains of these two molecules
showed that tyrosine-phosphorylated SLP-76 associates with
the SH2 domain near the N-terminus of p85 (N-SH2). Fur-
thermore, unlike the interaction of SLP-76with the SH2 domain
of Vav or Nck, which requires phosphorylation of SLP-76 ty-
rosines at positions 113 and 128, phosphorylation at either 113
or 128 is suﬃcient for binding of p85 N-SH2. Collectively, these
results indicate that SLP-76 is involved in the PI3K signaling
pathway.2. Materials and methods
2.1. Antibodies and other reagents
Anti-human CD3 monoclonal antibody (mAb) (UCHT1) from
BD PharMingen (San Diego, CA) was used for cell stimulation.
For immunoprecipitation (IP) and immunoblotting (IB), we usedblished by Elsevier B.V. All rights reserved.
Fig. 1. Expression of SLP-76 bait proteins and analyses of two-hybrid
interactions in yeasts. (A) Structure of various LexA fusion SLP-76
derivatives. (B) Yeast cells (EGY48) were transformed with plasmids
carrying LexA fusions of various SLP-76 derivatives. The LexA fusion
proteins present in cell lysates were fractionated by SDS–8% PAGE
and detected by immunoblotting (IB) with anti-LexA Ab. (C) After
transformation separately with either SLP-76 or a Syk kinase domain,
or with SLP-76 fused to a PTK kinase domain, lysates were subjected
to SDS–8% PAGE, and phosphorylation was detected by IB with anti-
phosphotyrosine (pY) Ab, 4G10. (D) The two p85 isolates obtained by
screening the human Jurkat T leukemia cDNA library with N-SLP-
SykK as bait were assayed for interaction with various SLP-76 baits.
Yeast cells were transformed with each target and the indicated SLP-76
bait plasmid along with a b-gal reporter gene. The tester strains were
streaked onto either induction/selection medium containing X-gal or a
non-inducing, non-selective medium, as a loading control (data not
shown). Three independent experiments involving independently de-
rived yeast tester strains yielded virtually identical results.
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phosphotyrosine (4G10) mAbs from Upstate Biotechnology, Inc.
(Lake Placid, NY), anti-SLP-76 polyclonal Ab and anti-LexA and
anti-GST mAbs from Santa Cruz Biotechnology, Inc. (Santa Cruz,
CA), and anti-ﬂag mAb (M2) from Sigma Chemical Co. (St Louis,
MO). Secondary Abs, anti-mouse IgG and anti-rabbit IgG conju-
gated with horseradish peroxidase (HRP) were purchased from Bio-
Rad (Hercules, CA). Glutathione-agarose and Coomassie brilliant
blue (CBB) R-250 from Sigma Chemical Co. were used for purifying
and identifying GST-fusion proteins, respectively. Enhanced chemi-
luminescence (ECL) reagents and GammaBind G Sepharose were
purchased from Amersham Pharmacia Biotech Co. (Arlington
Heights, IL).2.2. Plasmids
Mammalian expression vectors encoding myc-tagged human PI3K
p85a and Syk PTK were kindly provided by Drs. A. Toker (Harvard
Medical School, Boston, MA) and A. Veillette (McGill University,
Montreal, Canada), respectively. The plasmids carrying wild type (Wt)
SLP-76 and its mutants cloned into a modiﬁed pEF-Bos vector with an
amino-terminal sequence encoding the ﬂag epitope [3–5] were generous
gifts from Dr. G. Koretzky (University of Pennsylvania, Philadelphia,
PA).
Plasmids expressing glutathione S-transferase (GST) fusions of
truncated p85 and the SH2 domain of Vav, Nck, or Itk were generated
by ligating PCR fragments into pGEX-2TK (Amersham Pharmacia
Biotech Co., Arlington Heights, IL) between the BamH1 and EcoR1
sites. The truncated p85 constructs encoding the sequences indicated in
Fig. 3A (SH3-P-B-P including N-terminal SH3-proline rich-Bcr ho-
mology-proline rich domains, N-SH2, C-SH2, and N-I-C-SH2 in-
cluding N-SH2-inter-SH2-C-SH2) were ampliﬁed from human p85a
cDNA. The SH2 domain constructs encoding amino acids, 671–765,
282–376, and 671–765 of human Vav, Nck, and Itk, respectively, were
prepared from Jurkat cDNA by PCR ampliﬁcation.
A plasmid expressing a LexA DNA-binding domain (BD) fusion of
the complete SLP-76 gene was generated by PCR ampliﬁcation fol-
lowed by ligation into yeast expression vector pLexA (Clontech lab-
oratories Inc., Palo Alto, CA) at its BamH1 site (pLexA/SLP-76 Wt).
The N-SLP fragment ampliﬁed by PCR was ﬁrst ligated into pBlue-
script SK(+) vector (Stratagene, La Jolla, CA) at the BamH1 site, and
further cloned into pLexA between the EcoR1 and Not1 sites, followed
by ﬁlling at the EcoR1 site to put the sequence back in frame (pLexA/
N-SLP). A plasmid expressing a LexA fusion of C-SLP was generated
by PCR ampliﬁcation followed by ligation into pLexA between EcoR1
and BamH1 sites (pLexA/C-SLP). To generate the plasmid expressing
LexA/N-SLP-SykK, the kinase domain of Syk (amino acids 421–533
of mouse Syk) ampliﬁed by PCR was ﬁrst ligated into pBluscript
SK(+) between its BamH1 and EcoR1 sites, and further cloned into
pLexA/N-SLP between Not1 and Sal1 sites. To generate the fusion
plasmid expressing LexA/C-SLP-LckK(Y505F), the kinase domain of
Lck (constitutively active form, F505; amino acids 244–497) was am-
pliﬁed by PCR followed by ligation into pLexA/C-SH2 between
BamH1 and Sal1 sites. All the constructs were conﬁrmed free of
undesired mutations by sequencing.2.3. Yeast two-hybrid screen and assay
The MATCHMAKER LexA two-hybrid system (Clontech Labo-
ratories Inc.) was used to screen a human leukemia MATCHMAKER
LexA cDNA library (Clontech Laboratories Inc.), following the
manufacturer’s protocol. Brieﬂy, yeast strain EGY48 containing
the p80p-lacZ reporter (EGY48 [p80p-lacZ]) was transformed with the
LexA/N-SLP-SykK bait and the plasmid human leukemia cDNA li-
brary bearing the activation domain (AD) fusion constructed in
pB42AD. Transformants were selected on galactose induction medium
lacking histidine, leucine, tryptophan, and uracil, and the resulting
clones were analyzed for lacZ and LEU2 reporter genes. Plasmid DNA
was recovered from positive clones by transforming E. coli KC8 and
sequenced. To assay interaction of the positive clones with various
SLP-76 baits, EGY48 [p80p-lacZ] was transformed with each bait
plasmid constructed in pLexA(DNA-BD) and the pB42AD/positive
library plasmid. Colony selection and interaction analysis were
performed as above.
2.4. Cell culture and T cell activation
Human Jurkat T leukemia cells and human embryonic kidney
(HEK) 293T cells were cultured in RPMI 1640 medium and Dul-
becco’s modiﬁed Eagle’s medium, respectively, with 10% heat-
inactivated fetal calf serum (HI-FCS), 100 units/ml penicillin, 100 lg/
ml streptomycin, and 20 mM glutamine. The cell lines were maintained
at 37 C with 5% CO2/95% O2. For activation, Jurkat T cells were
washed and resuspended in RPMI 1640 medium at 1 107/ml and
incubated with either control Ab or anti-CD3 Ab for 5 min at 37 C.
2.5. Transient expression of plasmid DNA
HEK 293T cells were seeded 24 h before transfection at approxi-
mately 6 105 cells/60 mm culture dish. They were then transfected
with 5 lg each of the various expression plasmids by the calcium
phosphate precipitation method and the transfected cells were cultured
in growth medium for 24 h before performing experiments.
E.K. Shim et al. / FEBS Letters 575 (2004) 35–40 372.6. Immunoprecipitation and immunoblotting
T cell stimulation was terminated by adding an equal volume of ice-
cold medium, and cell lysates were prepared in 1% NP-40 lysis buﬀer
that contained protease and phosphatase inhibitors, as described pre-
viously [19]. For IB, lysates from 1 106 cells were mixed with 2X
Laemmli’s sample buﬀer, boiled, and subjected to SDS–10% PAGE.
For IP, lysates from 50 106 cells were tumbled with GammaBind G
sepharose beads conjugated with the individual Abs as indicated. The
immune complexes were then subjected to SDS–PAGE, followed by
IB.2.7. Precipitation of GST-fusion proteins
GST fusion proteins containing the SH2 domains of p85, Vav, Nck,
or Itk, as well as other domains of p85, were prepared as described
elsewhere [20], and bound to glutathione-coated agarose beads. Ly-
sates of HEK 293T cells transfected with various expression plasmids
were precleared with 5 lg GST immobilized on 10 ll of glutathione-
coated beads, followed by incubation for 2 h at 4 C with 10 lg of SH2
domain fusion proteins immobilized on 10 ll beads. Proteins bound to
the fusion proteins were separated by SDS–PAGE and transferred to
nitrocellulose membranes for IB.Fig. 2. Tyrosine phosphorylation of SLP-76, but not its SH2 domain,
mediates the association with p85 in vivo. (A) HEK 293T cells were
transfected with plasmids carrying either full-length SLP-76 (ﬂag) or
an SLP-76 mutant (SLPDSH2, ﬂag) along with p85 (myc). The cells
were either left untreated (control), or treated with pervanadate (PV)
for 5 min, and lysates were prepared and subjected to SDS–8% PAGE.
Protein expression was detected by IB with anti-ﬂag or anti-myc Ab.
Phosphorylation induced by the PV treatment was determined by IB
with 4G10 Ab (data not shown). Immunoprecipitates with anti-SLP-76
Ab, as well as control anti-mouse Ig (data not shown), were subjected
to SDS–8% PAGE. The amounts of IP from untreated or PV treated
lysates were determined by IB with anti-ﬂag Ab and tyrosine phos-
phorylation of SLP-76 following PV treatment was conﬁrmed by IB
with 4G10. Association between p85 and SLP-76 was detected by IB
using anti-myc Ab. Data shown are representatives of three separate
experiments. (B) Jurkat T cells were either left unstimulated (control)
or TCR stimulated for 5 min at 37 C. Lysates were immunoprecipi-
tated with Ab against either SLP-76 or p85. Immunoprecipitates were
subjected to SDS–8% PAGE and phosphorylation of SLP-76 following
TCR ligation was detected by IB with 4G10. To measure phosphor-
ylation-dependent association of SLP-76 with p85, the same blot was
reprobed with either anti-SLP-76, or with anti-p85 Ab to demonstrate
equal levels of IP as well as association of SLP-76 with p85. Data are
representatives of three independent experiments.3. Results
3.1. The amino-terminal region of SLP-76 (N-SLP) interacts
with p85 in a Syk-dependent yeast two-hybrid screen
We prepared LexA fusion bait plasmids that expressed
full-length SLP-76 (SLP-full), N-SLP, a fusion of N-SLP
with the kinase domain of Syk (N-SLP-SykK), the kinase
domain of Syk (SykK), C-SLP, and a fusion of C-SLP with
the kinase domain of constitutively active Lck (Y505F) (C-
SLP-LckK). Some of these bait plasmids are described
schematically in Fig. 1A and protein expression is shown by
immunoblotting (IB) yeast lysates with anti-LexA Ab in
Fig. 1B. Since three tyrosine residues within N-SLP represent
phosphorylation sites for the ZAP-70 and Syk PTKs, but not
for the Lck, and since unlike the activation of Syk, ZAP-70
activation requires the activity of LckK [1,2], the kinase
domain of Syk was fused to N-SLP to induce phosphoryla-
tion of SLP-76. In contrast, the kinase domain of constitu-
tively active Lck was fused to C-SLP to induce
phosphorylation of library proteins that may associate with
SLP-76 through the SH2 domain, since Lck is a primary
PTK that responds to T cell activation [24–27]. IB of yeast
lysates with anti-phosphotyrosine Ab revealed that expres-
sion of N-SLP-SykK, SykK, or C-SLP-LckK, but not N-SLP
or C-SLP, led to tyrosine phosphorylation of yeast proteins
(Fig. 1C). To search for molecules that interact with the
phosphotyrosine motifs of SLP-76, we expressed the LexA
fusion of N-SLP-SykK as bait to screen a human leukemia
cDNA library. We isolated 76 positive clones from 1.6 108
colony-forming units of the ampliﬁed library, representing
1.9 106 independent clones. Most of the isolates con-
tained cDNA fragments encoding the SH2 domains of
Vav-1, Nck-1, or Src-like adaptor protein (SLAP), but two
contained diﬀerent but overlapping fragments encoding the
SH2 domain of the p85 subunit of PI3K. These p85 isolates
were tested for interaction with the various SLP-76 baits
(Fig. 1D). SLP-76 baits not fused with the kinase domain of
a PTK interacted weakly if at all with the p85 clones. There
was a strong interaction with the N-SLP-SykK, but not with
C-SLP-LckK. These results indicate that N-SLP is phos-
phorylated by Syk kinase and then interacts with p85
through the p85 SH2 domain.3.2. Tyrosine-phosphorylated SLP-76 associates in vivo with the
amino-terminal SH2 domain of p85
To see whether SLP-76 associates with p85 in vivo and
whether tyrosine-phosphorylation of SLP-76, not of p85, is
required for their interaction, we transiently overexpressed
myc-tagged p85 in combination with ﬂag-tagged SLP-76 Wt or
a mutant lacking the SH2 domain (SLPDSH2) in HEK 293T
cells (Fig. 2A). When we induced tyrosine-phosphorylation of
SLP-76 Wt or SLPDSH2 by pervanadate (PV) stimulation of
the transfected cells, both the Wt and the mutant SLP-76
protein were immunoprecipitated with p85 (Fig. 2A). We also
tested for association of the endogenous proteins by per-
forming IP in Jurkat T cells. As shown in Fig. 2B, TCR
stimulation with anti-CD3 Ab induced phosphorylation of
SLP-76. p85 was detected in precipitates with anti-SLP-76 Ab
and SLP-76 was present in immunoprecipitates with anti-p85
Ab (Fig. 2B). These results show that SLP-76 associates with
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of the TCR.
We next asked which domain(s) of p85 associate(s) with
tyrosine-phosphorylated SLP-76. For these experiments, we
produced GST-fusions of a set of truncated p85 constructs as
described in Fig. 3A and conﬁrmed expression of these pro-
teins by immunoblotting with anti-GST Ab (Fig. 3B). We then
performed GST pull-down assays on lysates of HEK 293T
cells expressing ﬂag-tagged SLP-76 Wt together with either
empty vector or myc-tagged Syk PTK (Fig. 3C). As shown in
Fig. 3C and D, SLP-76 was phosphorylated and precipitated
with p85 GST-fusion proteins containing the N-SH2 domain
when Syk was expressed at the same time. No interaction was
detected between SLP-76 and GST on their own (data notFig. 3. Association of p85 with phosphorylated SLP-76 via the p85 N-
SH2 domain. (A) Structure of p85 and its truncated mutants. (B) GST
fusion proteins of p85 domain mutants were expressed and conﬁrmed
by IB using anti-GST Ab. (C) SLP-76 was expressed in HEK 293T
cells in the presence or absence of Syk. Expression of proteins was
detected by IB using anti-ﬂag or anti-myc Ab. Protein phosphorylation
induced by Syk kinase was determined by IB lysates of HEK293T cells
with 4G10. Phosphorylation of SLP-76 in the presence of Syk was also
conﬁrmed by IP of cell lysates with anti-ﬂag Ab followed by IB with
4G10. (D) GST fusions of the p85 domain mutants were incubated
with lysates of HEK 293T cells expressing SLP-76 with or without Syk.
Association of SLP-76 with p85 was detected by IB using anti-ﬂag Ab.
Data shown are representatives of three separate experiments.shown), further indicating that SLP-76 binds speciﬁcally to the
N-SH2 of p85.
3.3. Tyrosine phosphorylation of SLP-76 at position 113 or 128
is suﬃcient for binding to the N-SH2 domain of p85
To conﬁrm the association of the p85 N-SH2 with tyrosine-
phosphorylated SLP-76, we overexpressed various ﬂag-tagged
SLP-76 mutants in HEK 293T cells together with either empty
vector or myc-tagged Syk (Fig. 4A). The SLP-76 mutants in-
cluded a deletion of the N-terminal acidic region (D156), as
well as point mutants of the tyrosine motifs (Y113, 128F and
Y3F). Lysates of the transfected HEK 293T cells were thenFig. 4. Phosphorylation of SLP-76 at tyrosines 113 and/or 128 is re-
quired for association with p85 N-SH2. SLP-76 Wt, an N-terminal
deletion mutant, and various tyrosine substitution mutants were ex-
pressed in HEK 293T cells in the presence or absence of Syk. Protein
expression was determined by IB with anti-ﬂag or anti-myc Ab and
phosphorylation of various SLP-76 induced by Syk kinase was deter-
mined by IP with anti-ﬂag Ab followed by IB with 4G10. Association
of SLP-76 with p85 N-SH2 (A and B) or Vav SH2 (B) was measured as
described in Fig. 3D. GST fusion proteins of p85 N-SH2 and Vav SH2
were expressed and conﬁrmed by staining with CBB. Representative
data from three independent experiments are shown.
Fig. 5. Diﬀerential phosphorylation of SLP-76 tyrosine motifs required
for association with the SH2 domain of Nck or Itk. Expression of SLP-
76 (Wt or various tyrosine mutants) with or without Syk kinase was
determined in HEK 293T cells by IB of lysates with anti-ﬂag or anti-
myc Ab. Phosphorylation of various SLP-76 induced by Syk was de-
termined by IP of lysates with anti-ﬂag Ab followed by IB with 4G10.
Association of SLP-76 (Wt or mutants) with the SH2 domains of Nck
or Itk was detected by IB with anti-ﬂag Ab as described in Fig. 3D.
GST fusion proteins of Nck SH2 and Itk SH2 were expressed and
conﬁrmed by staining with CBB. The experiments were repeated three
times and representative data are shown.
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SLP-76 lacking its N-terminal region did not interact with p85
N-SH2 (Fig. 4A). Similarly, there was no Syk-dependent as-
sociation of p85 N-SH2 with a mutant Y113, 128F, in which
the tyrosines (Y) at positions 113 and 128 in the two ‘‘YESP’’
motifs were changed to phenylalanine (F), or with a mutant
Y3F, with all three Ys, at positions 113, 128, and 145, changed
to Fs (Fig. 4A). These results further indicate that phosphor-
ylation of tyrosines at positions 113 and 128 is required for the
SLP-76 association with p85.
Since the two ‘‘YESP’’ motifs that are strong substrates for
PTKs [2,3] are also required for binding of SLP-76 to the SH2
domain of Vav [6–9], we next compared binding of SLP-76
with the SH2 domains of Vav and p85. For these experiments,
the single tyrosine mutants of SLP-76, Y113F and Y128F were
expressed in HEK 293T cells together with empty vector or
Syk PTK (Fig. 4B). Lysates of the transfected cells were then
incubated with the fusion proteins GST-p85 N-SH2 or GST-
Vav SH2. As shown previously [7,9] and in Fig. 4B, binding of
Vav SH2 to SLP-76 required tyrosine phosphorylation at 113
and 128. In contrast, phosphorylation of tyrosine at either 113
or 128 was suﬃcient for binding to p85 N-SH2, although
phosphorylation at 113 seems to be more inﬂuential (Fig. 4B).
We next examined the preference of the SLP-76 tyrosine
motifs for binding to other SH2 domains that associate with
SLP-76. Since the SH2 domains of Nck and Itk associate with
the phosphotyrosines of SLP-76 [21–23], we performed a pull-
down assay using GST-fusion proteins of the SH2 domains of
Nck and Itk with lysates of HEK 293T cells overexpressing
SLP-76 mutants Y113F, Y128F, or Y113, 128F, together with
either vector or Syk PTK (Fig. 5). Nck SH2 associated
strongly with SLP-76 Wt in a Syk-dependent manner. Binding
was, however, dramatically reduced with the single tyrosine
mutant, Y113F or Y128F, and completely absent with the
double tyrosine mutant, Y113, 128F (Fig. 5). This pattern of
binding is similar to that observed with Vav SH2 (Fig. 4B).
Although the association was weak, Itk SH2 also bound to
SLP-76 in a Syk-dependent binding manner (Fig. 5). As in
binding to p85 SH2 (Fig. 4B), the pYESP motif at 113 dom-
inated. These results indicate that the pYESP motifs of SLP-76
diﬀer in their aﬃnities for the SH2 domains of various mole-
cules forming functional molecular complexes during T cell
activation.4. Discussion
Ligation of the TCR results in the sequential activation of
members of two PTK families such as the Src (p56lck/p59fyn)
and Syk (Syk/ZAP-70) families [24–27]. Tyrosine phosphor-
ylation of receptor-associated ZAP-70 by p56lck is required
for upregulation of ZAP-70 catalytic activity required for
TCR function [28,29]. Since activation of these kinases is the
most membrane-proximal biochemical event known follow-
ing TCR engagement, and since phosphorylation of cellular
proteins by these kinases is essential for all subsequent TCR-
initiated signaling pathways, a number of researchers have
attempted to identify the substrates of these PTKs. One of
the substrates identiﬁed is the hematopoietic cell-speciﬁc
molecule, SLP-76, which is phosphorylated by ZAP-70 [2]
and plays key roles in the regulation of TCR signals [3–5].To identify molecules that associate with the three tandemly
repeated DYE(S/P)P sequences of SLP-76 in activated T
cells, we screened a human T leukemia cDNA library using
the yeast two-hybrid method.
The screen revealed the regulatory subunit of PI3K, p85,
as a novel molecule interacting with SLP-76 (Fig. 1). We
performed a series of experiments to conﬁrm the association
of SLP-76 with p85 in HEK 293T cells, in which we over-
expressed various proteins, as well as in Jurkat T cells
(Fig. 2). We further demonstrated that one of the phos-
photyrosines, at positions 113 and 128, is required for as-
sociation of SLP-76 with the N-SH2 of p85 (Figs. 3 and 4).
We also showed that whereas the association of the SH2
domains of Vav and Nck with SLP-76 requires tyrosine
phosphorylation at both 113 and 128, tyrosine phosphory-
lation at either 113 or 128 is suﬃcient for association with
the SH2 domains of p85 and Itk (Figs. 4 and 5). These re-
sults suggest that diﬀerences in the extent of tyrosine phos-
phorylation following T cell activation may lead to the
formation of distinct signaling complexes around the SLP-76
adapter molecule.
In summary, this report is the ﬁrst to show that the T cell
adapter, SLP-76, associates with p85, a subunit of PI3K, in an
activation-dependent manner and that phosphorylation of
tyrosine at 113 preferentially mediates the interaction with the
N-SH2 of p85. Further understanding the functional role of
this intracellular complex formed upon activation of T cells
may help to elucidate a new signaling pathway regulated by
SLP-76.
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